Screening strategies for ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 1, 1998, Pages 33-39

  Collins, William P ^a,c   Bourne, Thomas H ^b   Campbell, Stuart ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; COLONY STIMULATING FACTOR 1; GENE PRODUCT; PROTEIN P53;

AGING; BLOOD FLOW VELOCITY; BREAST CARCINOMA; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; COLORECTAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; META ANALYSIS; OVARY CARCINOMA; PEDIGREE ANALYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TRANSVAGINAL ECHOGRAPHY; TUMOR VASCULARIZATION;

ANTIGENS, NEOPLASM; ENDOSONOGRAPHY; FEMALE; GENES, BRCA1; HUMANS; IMMUNOASSAY; MUTATION; OVARIAN NEOPLASMS; ULTRASONOGRAPHY, DOPPLER, COLOR; VAGINA;

EID: 0031914588     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199802000-00007     Document Type: Review

References (56)

1. Schwartz PE, Chambers JT, Taylor KJ. Early detection and screening for ovarian cancer. J Cell Biochem 1995; 23:233-237.
2. Guidozzi F. Screening for ovarian cancer. Obstet Gynecol Surv 1996; 51:696-701.
3. Crvenkovic G, Karlan BY, Platt LD. Current role of ultrasound in ovarian cancer screening. Clin Obstet Gynecol 1996; 39:259-267.
4. Kramer BS, Gohagan J, Prorok PC, Smart CA. National Cancer Institute sponsored screening trial for prostatic, lung, colorectal and ovarian cancer. Cancer 1993; 71:589-593.
5. Parkes CA, Smith D, Wald NJ, Bourne TH. Feasibility study of a randomised trial of ovarian cancer screening among the general population. J Med Screen 1994; 1:209-214.
6. NIH Consensus Development Panel on Ovarian Cancer. Ovarian cancer: screening, treatment, and follow-up. JAMA 1995; 273:491-497.
7. Cancer facts and figures - 1996. Atlanta: American Cancer Society; 1996.
8. Pettersson F (ed). Annual FIGO Report on the results of treatment in gynecological cancer, volume 22, Stockholm: Repro Print; 1995. pp. 83-102.
9. Young RC, Warion LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG. Adjuvant therapy in stage I and stage II epithelial ovarian cancers - results of two prospective randomised trials. N Engl J Med 1990; 322:1021-1027.
10. Espey LL. Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction. Biol Reprod 1994; 50:233-238.
11. Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. BMJ 1989; 299:1363-1367.
12. Bhan V, Amso N, Whitehead MI, Campbell S, Royston P, Collins WP. Characteristics of persistent ovarian masses in asymptomatic women. Br J Obstet Gynaecol 1989; 96:1384-1391.
13. Kairisto V, Poola A. Software for illustrative preparation of basic clinical characteristics of laboratory tests - Graph ROC for Windows. Scand J Clin Lab Invest 1995; 55 (Suppl.222):43-60.
14. Wittemore AS, Harris R, Itnyre J, Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992; 136:1184-1203.
15. Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140:585-597.
16. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993; 71:566-572.
17. Easton DF, Matthews FE, Ford D, Swerdlow AJ, Peto J. Cancer mortality in relatives of women with ovarian cancer: the OPCS study. Int J Cancer 1996; 65:284-294.
18. Schildkraut JM, Risch N, Thompson WD. Evaluating genetic association among ovarian, breast and endometrial cancer: evidence for a breast/ovarian relationship. Am J Hum Genet 1989; 45:521-529.
19. Houlston RS, Collins A, Slack J, Campbell S, Collins WP, Whitehead MI, Morton NE. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet 1991; 55:291-299.
20. Steichen-Gersdorf E, Gallion HH, Ford D, Girodet C, Easton DF, DiCoccio RA, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet 1994; 55:870-875.
21. Narod SA, Ford D, Devilee P, Barkadoffir RB, Lynch HT, Smith SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet 1995; 56:254-264.
22. Ford D, Easton DF, Peto J, Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57:1457-1462.
23. Vasen HF, Wijnen JT, Menko FH, Kleibeuker JH, Taal BG, Griffioen G, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996; 110:1020-1027.
24. Bourne TH, Campbell S, Reynolds K, Hampson J, Bhatt L, Crayford TJB, et al. The potential role of serum CA-125 in an ultrasound based screening program for familial ovarian cancer. Gynecol Oncol 1994; 52:379-385.
25. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour flow imaging. BMJ 1993; 306:1025-1029.
26. De Priest PD, Varner E, Powell J, Fried A, Puls L, Higgins R, et al. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol 1994; 55:174-178.
27. Tekay A, Jouppila P. Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 1995; 75:316-329.
28. Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 1995; 76:1214-1218.
29. Karlan BY. The status of ultrasound and color Doppler imaging for the early detection of ovarian carcinoma. Cancer Invest 1997; 15:265-269. This paper acknowledges the high sensitivity of ultrasonography and emphasizes the problems of specificity and reproducibility. The possible use of alternative imaging techniques is mentioned.
30. Hata K, Hata R, Kitao M. Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. Am J Obstet Gynecol 1995; 172:1496-1500.
31. Tailor A, Jurkovic D, Bourne TH, Natucci M, CollinsWP, Campbell S. A comparison of intra tumoural indices of blood flow velocity and impedance for the diagnosis of ovarian cancer. Ultrasound Med Biol 1996; 22:837-843. The results of this study provide further evidence for the value of indices of intra-tumoural blood velocity in the diagnosis of invasive disease.
32. De Priest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997; 65:408-414. The results of this clinical trial of ultrasound-based screening for sporadic and familial ovarian cancer provide further evidence of high sensitivity for stage I disease and support the need for multi-centre studies.
33. Dorum A, Kristensen GB, Abeler VM, Tropé CG, Moller P. Early detection of familial ovarian cancer. Eur J Cancer 1996; 32:1645-1651. This is the first report of the high prevalence of ovarian cancer in a prospective screening study of women with the BOC syndrome.
34. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121:124-132.
35. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306:1030-1034.
36. Hakama M, Stenman U-H, Knekt P, Järvisalo J, Hakulinen T, Maatela J, Aromaa A. CA 125 as a screening test for ovarian cancer. J Med Screen 1996; 3:40-42.
37. Vuento MH, Stenman U-H, Pirhonen JP, Mäkinen JI, Laippala PJ, Salmi TA. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecol Oncol 1997; 64:141-146.
38. Whitmore SE, Anhalt GJ, Provost TT, Zacur HA, Hamper UM, Helzlsouer KJ, Rosenshein NB. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 1997; 65:241-244.
39. Jacobs IJ, Skates S, Prys Davies A, Woolas RP, Jeyerajah A, Weidemann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996; 313:1355-1358. The authors show that the level of circulating CA 125 is a powerful index of risk for ovarian or fallopian tube cancer in asymptomatic postmenopausal women.
40. Woolas RP, Xu F-J, Jacobs IJ, Yu Y-H, Daly L, Berchuck A, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst 1993; 85:1748-1751.
41. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 1995; 59:111-116.
42. Rustin GJS. Circulating tumor markers in gynecological tumors. Curr Opin Obstet Gynecol 1996; 8:426-431.
43. Schwartz PE, Cracchiolo BM, Cole LA. Clinical applications of urinary gonadotrophin peptides (UGP) in gynecologic oncology. Anticancer Res 1996; 16:2135-2139.
44. Vennegoor CJGM, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, von Mendsdorff-Pouilly S, et al. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett 1997; 116:93-101.
45. Skates SJ, Xu F-J, Yu Y-H, Sjövall K, Einhorn N, Chang Y-C, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76:2004-2010.
46. Granberg S, Wikland M, Bourne TH, Hamberger L. Transvaginal ultrasound-guided ovarian endoscopy: a novel approach to the assessment of ovarian tumors. Ultrasound Obstet Gynecol 1994; 4:130-134.
47. Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynecol 1997; 10:41-47. The authors report that logistic regression analysis of a few simple indices (e.g. age, papillary projection into a cyst, TAMXV) can be used to efficiently differentiate between malignant and benign pelvic masses.
48. Langston AA, Ostrander EA. Hereditary ovarian cancer. Curr Opin Obstet Gynecol 1997; 9:3-7.
49. Gather SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder BAJ. Rapid detection of regionally clustered germ-line mutations by multiple heteroduplex analysis. Am J Hum Genet 1996; 58:451-456. The authors report a technique that can be used to detect about 50% of all BRCA1 mutations in women with the BOC syndrome.
50. Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 1996; 175:738-746.
51. Beckmann MW, Schnürch HG, Bodden-Heidrich R, Mosny DS, Crombach G, Nitz U, et al. Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines. Eur J Cancer Prev 1996; 5:468-475.
52. ACOG Committee Opinion. Breast-ovarian cancer screening. Int J Gynecol Obstet 1997; 56:82-83.
53. Cole DEC, Gallinger S, McCready DR, Rosen B, Engel J, Malkin D. Genetic counselling and testing for susceptibility to breast, ovarian and colon cancer: where are we today? Can Med Assoc 1996; 154:149-155.
54. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol 1997; 64:196-206. The authors provide a comprehensive, well-referenced review of the molecular genetics of hereditary ovarian cancers, the clinical implications, and recommendations for management.
55. Burke W, Daly M, Garber J, Botkin J, Ellis Kahn MJ, Lynch P, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. Consensus Statement for the Cancer Genetics Studies Consortium. JAMA 1997; 277:997-1003.
56. Bombard AT, Fields AL, Aufox S, Ben-Yishay M. The genetics of ovarian cancer: an assessment of current screening protocols and recommendations for counseling families at risk. Clin Obsfet Gynecol 1996; 39:860-872.